We have assembled a highly qualified management team with broad and deep oncology and biotech experience to execute on our mission to develop novel precision oncology therapies based on synthetic lethality.
Lloyd M. Segal
President & CEO
Lloyd M. Segal has served as our President and CEO and as a member of our board of directors since our incorporation in September 2016. From 2010 to 2016, he was a Managing Partner with Persistence Capital Partners, a Canadian-based healthcare private equity investor. Previously, Mr. Segal was a consultant with McKinsey & Company, and served as CEO of several emerging biotechnology companies including Advanced Bioconcept Inc., Caprion Pharmaceuticals Inc. (now CellCarta), which he co-founded, and Thallion Pharmaceuticals Inc.
He serves as a member of the board of directors of GBC American Fund, a U.S. growth-focused mutual fund and of Aktis Oncology, a private developer of oncology radiopharmaceuticals. Mr. Segal also previously served as Chairman of LMC Diabetes & Endocrinology, Canada’s leading national endocrinology practice. From 2016 to 2020, Mr. Segal served as Entrepreneur-in-Residence with Versant Ventures. He was honored in 2013 by the Financial Times as Outstanding Director of the Year for public companies and also previously served on the boards of directors of several public and private U.S. and Canadian companies.
Mr. Segal received a B.A. in politics from Brandeis University and an M.B.A. from Harvard Business School.
EVP, Chief Financial Officer
Steve Forte has served as our Executive Vice President, Chief Financial Officer since October 2019. Prior to joining us, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc. from August 2018 through June 2019, during which time Clementia was acquired by Ipsen S.A. From September 2015 to August 2018, Mr. Forte served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments.
From September 2014 to September 2015, he served as Executive Director of Finance of CST Canada Co. From 2005 to 2014, Mr. Forte held positions of increasing responsibility at Aptalis Pharma Inc., including most recently holding the position of Vice President, Financial Reporting where he was responsible for the overall corporate controllership function of the company.
Mr. Forte received a Bachelor of Commerce in accountancy from Concordia University and is a Certified Professional Accountant in the Province of Québec and a Certified Information Systems Auditor (non-practicing) with ISACA.
EVP, Commercial & New Product Development
Phillip Herman has served as our Executive Vice President, Commercial & New Product Development since January 2022. Mr. Herman brings extensive commercial experience with a focus in oncology and rare diseases and has a proven track record of product launches across a broad spectrum of therapeutic areas.
Mr. Herman most recently served as the Chief Commercial Officer of Y-mAbs Therapeutics where he led the successful launch and commercialization of DANYELZA® (naxitamab). He served in this role from June 2018 to December 2021. Prior to Y-mAbs, Mr. Herman held various commercial and marketing positions including VP, Head of Santhera U.S. and Head of Commercial, Head of Marketing at Dyax, Director of Marketing at Vanda Pharmaceuticals, and various positions of increasing responsibility at Pfizer Inc.
Mr. Herman received a B.A. in business administration from Baldwin Wallace University, and an M.B.A. from the Kellogg School of Management at Northwestern University.
Maria Koehler, M.D., Ph.D.
EVP & Chief Medical Officer
Maria Koehler, M.D., Ph.D. has served as our Executive Vice President, Chief Medical Officer since May 2019. Prior to joining us, from September 2017 to April 2019, Dr. Koehler served as the Chief Medical Officer of Bicycle Therapeutics Limited. From March 2009 to September 2017, Dr. Koehler served as Vice President in Oncology Reserarch and Development, most recently as VP of Strategy, Innovation and Collaborations for the Oncology Business Unit at Pfizer Inc. Prior to joining Pfizer, Dr. Koehler was the group leader for the Medicine Development Center of GlaxoSmithKline Oncology.
Prior to that, Dr. Koehler was a Senior Medical Director for oncology research and development at AstraZeneca plc. Dr. Koehler has also served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh as well as the director of the Bone Marrow Transplant Program and associate professor at St. Christopher’s Hospital in Philadelphia. Dr. Koehler serves as an independent director on the boards of directors of Ikena Therapeutics and Silverback Therapeutics.
Dr. Koehler is a board-certified hematology/oncology physician. Dr. Koehler received an M.D. and Ph.D. from Silesian School of Medicine in Katowice, Poland.
Michael Zinda, Ph.D.
EVP, Chief Scientific Officer
Michael Zinda, Ph.D. has served as our Executive Vice President, Chief Scientific Officer since May 2019 and previously served as Executive Vice President, Head of Research and Development of our U.S. subsidiary, Repare Therapeutics USA Inc., from June 2017 to May 2019. Prior to joining us, he spent 16 years at AstraZeneca from 2001 to May 2017, where he obtained the position of Executive Director, Head of Cancer Bioscience.
In this role, Dr. Zinda served on the global science leadership team, oncology research board and the Acerta research and early development teams accountable for strategy, key collaborations/partnerships and delivery of an innovative portfolio of patient-centric drug discovery programs.
Dr. Zinda received a B.Sc. in biology from Minnesota State University Moorhead and a Ph.D. in molecular biology from Vanderbilt University. He received his post-doctoral training at Princeton University and Eli Lilly & Company.
Cameron Black, Ph.D.
Cameron Black, Ph.D. has served as our Executive Vice President, Discovery since June 2016. Prior to joining us, Dr. Black co-founded Kanyr Pharma in 2013 and Kaneq Pharma in 2010 to develop drugs targeting cancer and metabolic disease, respectively. Prior to that, he spent nearly two decades at the Merck Frosst Center for Therapeutic Research, where he was responsible for the identification of seven drug candidates.
He led both the discovery and early clinical development of the cathepsin K inhibitor, odanacatib, a once-weekly treatment for osteoporosis. In 2010, he was made Site Scientific Operations Lead, responsible for the objectives and staffing of all discovery programs at Merck Frosst.
Dr. Black received a B.Sc. in chemistry from the University of Saskatchewan and a Ph.D. in chemistry from Harvard University.
Kim Seth, Ph.D.
EVP, Chief Business Officer
Kim Seth, Ph.D. has served as our Executive Vice President, Chief Business Officer since June 2017. Prior to joining us, from July 2015 to May 2017, he served as Chief Business Officer, and Chief Operating Officer at Resilience Therapeutics, Inc., where he was a co-founder and member of the Board of Directors. From February 2014 to January 2015, Dr. Seth served as Senior Vice President and Chief Business Officer at Epirus Pharmaceuticals, Inc., and from January 2011 to February 2014, he served as Executive Director, Worldwide R&D, at Pfizer Inc., where he held both global operational and strategy leadership positions.
In his role as Head, External Strategy & Innovation at Pfizer, Dr. Seth led strategic initiatives to enter and expand into new markets, including leading the strategy development and operational launch of Pfizer’s integrated Immuno-Oncology platform. As Head, Research Investments, he helped lead the design and execution of Pfizer’s R&D operational turnaround. Prior to joining Pfizer, Dr. Seth was Vice President at Goldman Sachs, where he was an investment research analyst covering global large-cap and specialty pharmaceuticals sectors.
Dr. Seth received an A.B. cum laude in economics from Harvard College and a Ph.D. in neurobiology from Harvard University.